A small proportion of veterans who went from a metered-dose inhaler to a dry-powder inhaler had to revert to the metered-dose ...

Doses of fluticasone propionate inhalation powder 50 and 100 mcg twice daily significantly improved FEV1 (15% and 18% change from baseline at Endpoint, respectively) compared with placebo (7% change).

Interventions: Patients entered a 4-week, open run-in period, receiving fluticasone propionate 50µg twice daily via a Diskus™ inhalation device. Patients whose asthma was well controlled ...

The researchers found that dry powder triple inhaler therapy of fluticasone-umeclidinium-vilanterol resulted in fewer COPD exacerbations compared to metered dose triple inhaler therapy of ...

a twice-daily metered dose inhaler, and fluticasone-umeclidinium-vilanterol, a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score ...

The other single-inhaler on the market for COPD triple therapy, fluticasone-umeclidinium-vilanterol, is a dry-powder inhaler that does not contain hydrofluoroalkane-134a. In a 2024 JAMA report ...

The abbreviated new drug application (ANDA) for the fluticasone propionate and salmeterol inhalation powder – named VR 315 – will see Vectura receive $10 million for its part in the drug's ...

Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate ... 500µg twice daily from a Diskus™ inhaler for a 4-week run-in period, dependent ...